Is oral semaglutide a promising alternative in treating diabetes, heart disease?

New research suggests that the oral version of semaglutide, the active ingredient in injectable drugs like Ozempic, may also help treat diabetes and heart disease. Image credit: Pixel Stories/Stocksy.

A new clinical trial in Italy investigates the efficacy of oral semaglutide.

Semaglutide and other GLP-1 agonist drugs to treat diabetes, cardiovascular health, and weight loss, are most widely available as injectable medications.. The study finds that oral versions of the drug perform best in patients in the early stages of diabetes, and not as well as injectables for other people.. Even though doses of oral semaglutide are significantly larger than injectable medications, far less of it gets into the blood stream, potentially reducing its effectiveness.

Semaglutide, the active ingredient in diabetes drugs that have also become popular as a weight-loss aid, is primarily available in injectable form.

This includes the two most widely used drugs, Wegovy and Ozempic. Rybelsus is currently the only oral semaglutide drug on the market.

In a new Italian study conducted in a clinical setting, oral semaglutide was found to be most effective in people with a recent diagnosis of diabetes.

People whose diabetes was recently diagnosed showed significant improvements in levels of HbA1c — a measurement of blood sugar — and their body weight.

The study results appear in the Journal of Clinical Medicine.

For more information on compounded semaglutide

click here. 

"from Medical News Today" 

Talk to one of our telehealth providers today.  Click Here